Early detection of heart failure receives a boost with Ultromics securing a substantial $55 million investment for expansion.
In a significant leap forward for cardiology, Ultromics, a leading company in AI-driven diagnostics, has secured $55 million in its Series C funding round. The funding, co-led by L&G, Allegis Capital, and Lightrock, along with continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University, will enable Ultromics to expand across the US and other key markets.
The focus of Ultromics' platform is to bring AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. This is particularly crucial for conditions like Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, where up to 64% of cases go undiagnosed and are often mistaken for more common forms of heart disease.
Ultromics' flagship product, EchoGo, is an AI platform that generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo is fully reimbursed under the USA's Medicare program, making it scalable across hospitals, clinics, and health systems nationwide.
In 2025, Ultromics launched EchoGo Score, a new feature that adds AI-driven probability scoring to EchoGo Heart Failure. This innovative tool is now Medicare-reimbursed for both outpatient and inpatient use, and it helps clinicians detect HFpEF with greater nuance.
Moreover, Ultromics has received FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024. This clearance marks a significant milestone, as Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help detect HFpEF and cardiac amyloidosis.
The impact of these AI diagnostics is substantial. They enable earlier detection of subtle and asymptomatic cardiac abnormalities, allowing proactive clinical intervention. They improve diagnostic accuracy and reduce human interpretation errors and variability, speeding up clinical workflows. AI-assisted platforms can integrate multimodal data (ECG, echo, labs), enhancing diagnostic precision beyond conventional imaging alone.
By facilitating early and accurate diagnosis, these tools have the potential to improve patient outcomes, reduce hospitalizations, and optimize resource utilization in cardiac care. When paired with the latest treatment advances, Ultromics' diagnostic approach is expected to help save lives.
The company aims to make AI-enhanced diagnostics a default step in cardiac examinations, contributing to a transformative advance in detecting HFpEF and cardiac amyloidosis. As these AI cardiology platforms continue to be clinically validated and adopted throughout 2025, they reinforce their growing role in enhancing cardiovascular diagnostics and management. However, ongoing large-scale prospective studies are essential to fully establish the clinical impact and integration pathways of these AI-driven tools in routine cardiology practice.
Meanwhile, other AI platforms are also making strides in the field. For instance, Nanox has received CE mark for its AI-powered spine assessment software, and the Institute of Tissue Medicine of the University of Bern has deployed digital pathology for diagnostics in the cloud with AWS. These developments underscore the significant advancements in AI-driven diagnostics, with potential to revolutionize the early detection and management of complex cardiac conditions.
Sources: 1. Digital Health & AI News 2. "AI-enabled echocardiography platforms for the diagnosis of cardiac amyloidosis: a systematic review" - Journal of Cardiovascular Medicine 3. "Deep learning for the diagnosis of heart failure with preserved ejection fraction" - Circulation: Cardiovascular Imaging
- The Series C funding round of Ultromics, a pioneering company in digital health and artificial intelligence, will be used to expand their AI-driven cardiology platform across the US and other key markets, focusing on early detection of high-risk medical-conditions like Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis.
- With FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024, Ultromics has become the first company to offer a Medicare-reimbursed, FDA-cleared AI technology for the detection of HFpEF and cardiac amyloidosis, enhancing health-and-wellness outcomes.
- AI-assisted diagnostics, such as Ultromics' EchoGo platform, are projected to revolutionize the healthcare industry by improving diagnostic accuracy, reducing human interpretation errors, and potentially reducing hospitalizations and optimizing resource utilization in cardiac care.
- The development and integration of AI platforms like Ultromics and Nanox, alongside ongoing large-scale studies, are expected to create a significant impact on the early detection and management of complex cardiac conditions, ultimately saving lives and promoting a transformative advance in healthcare technology.
